BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 33620658)

  • 1. Promoter hypomethylation as potential confounder of Ras gene overexpression and their clinical significance in subsets of urothelial carcinoma of bladder.
    Tripathi K; Goel A; Singhai A; Garg M
    Mol Biol Rep; 2021 Mar; 48(3):2183-2199. PubMed ID: 33620658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
    Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
    Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OASIS/CREB3L1 is epigenetically silenced in human bladder cancer facilitating tumor cell spreading and migration in vitro.
    Rose M; Schubert C; Dierichs L; Gaisa NT; Heer M; Heidenreich A; Knüchel R; Dahl E
    Epigenetics; 2014 Dec; 9(12):1626-40. PubMed ID: 25625847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
    Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
    Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA Hypomethylation Is Associated with the Overexpression of INHBA in Upper Tract Urothelial Carcinoma.
    Kao CC; Chang YL; Liu HY; Wu ST; Meng E; Cha TL; Sun GH; Yu DS; Luo HL
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insights into the influence of cigarette smoking on urothelial carcinogenesis: smoking-induced gene expression in tumor-free urothelium might discriminate muscle-invasive from nonmuscle-invasive urothelial bladder cancer.
    Gabriel U; Li L; Bolenz C; Steidler A; Kränzlin B; Saile M; Gretz N; Trojan L; Michel MS
    Mol Carcinog; 2012 Nov; 51(11):907-15. PubMed ID: 21976419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylation of a CpG island within the uroplakin Ib promoter: a possible mechanism for loss of uroplakin Ib expression in bladder carcinoma.
    Varga AE; Leonardos L; Jackson P; Marreiros A; Cowled PA
    Neoplasia; 2004; 6(2):128-35. PubMed ID: 15140401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between aberrant methylation of FAS promoter and biological behavior of bladder urothelial carcinoma.
    Li W; Xia D; Wang Y; Li Y; Xue Y; Wu X; Ye Z
    J Huazhong Univ Sci Technolog Med Sci; 2011 Dec; 31(6):794-798. PubMed ID: 22173501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases.
    Castillo-Martin M; Collazo Lorduy A; Gladoun N; Hyun G; Cordon-Cardo C
    J Pediatr Urol; 2016 Apr; 12(2):91.e1-7. PubMed ID: 26522772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder Cancer.
    Kitchen MO; Bryan RT; Haworth KE; Emes RD; Luscombe C; Gommersall L; Cheng KK; Zeegers MP; James ND; Devall AJ; Fryer AA; Farrell WE
    PLoS One; 2015; 10(9):e0137003. PubMed ID: 26332997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic inactivation of ST6GAL1 in human bladder cancer.
    Antony P; Rose M; Heidenreich A; Knüchel R; Gaisa NT; Dahl E
    BMC Cancer; 2014 Dec; 14():901. PubMed ID: 25465919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation and expression of LINE-1 and HERV-K provirus sequences in urothelial and renal cell carcinomas.
    Florl AR; Löwer R; Schmitz-Dräger BJ; Schulz WA
    Br J Cancer; 1999 Jul; 80(9):1312-21. PubMed ID: 10424731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma.
    Duarte-Pereira S; Paiva F; Costa VL; Ramalho-Carvalho J; Savva-Bordalo J; Rodrigues A; Ribeiro FR; Silva VM; Oliveira J; Henrique R; Jerónimo C
    Eur J Cancer; 2011 May; 47(7):1106-14. PubMed ID: 21273058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accurate detection of upper tract urothelial carcinoma in tissue and urine by means of quantitative GDF15, TMEFF2 and VIM promoter methylation.
    Monteiro-Reis S; Leça L; Almeida M; Antunes L; Monteiro P; Dias PC; Morais A; Oliveira J; Henrique R; Jerónimo C
    Eur J Cancer; 2014 Jan; 50(1):226-33. PubMed ID: 24100025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancer.
    Kitchen MO; Bryan RT; Emes RD; Glossop JR; Luscombe C; Cheng KK; Zeegers MP; James ND; Devall AJ; Mein CA; Gommersall L; Fryer AA; Farrell WE
    Epigenetics; 2016 Mar; 11(3):237-46. PubMed ID: 26929985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA hypermethylation on multiple CpG islands associated with increased DNA methyltransferase DNMT1 protein expression during multistage urothelial carcinogenesis.
    Nakagawa T; Kanai Y; Ushijima S; Kitamura T; Kakizoe T; Hirohashi S
    J Urol; 2005 May; 173(5):1767-71. PubMed ID: 15821584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A DNA hypermethylation profile reveals new potential biomarkers for the evaluation of prognosis in urothelial bladder cancer.
    López JI; Angulo JC; Martín A; Sánchez-Chapado M; González-Corpas A; Colás B; Ropero S
    APMIS; 2017 Sep; 125(9):787-796. PubMed ID: 28586118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA methylation alterations in urothelial carcinoma.
    Neuhausen A; Florl AR; Grimm MO; Schulz WA
    Cancer Biol Ther; 2006 Aug; 5(8):993-1001. PubMed ID: 16775427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma.
    Dhawan D; Hamdy FC; Rehman I; Patterson J; Cross SS; Feeley KM; Stephenson Y; Meuth M; Catto JW
    J Pathol; 2006 Jul; 209(3):336-43. PubMed ID: 16639696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
    Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
    BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.